Articles

Availability of Insulin Products Will Help Increase Access and Potentially Lower the Cost of Insulin for People with Diabetes Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes…

Chronic wounds are a ubiquitous cause of suffering for humanity worldwide. Despite payors spending vast sums for treatment, suffering continues largely unabated. As part of its concerted effort to bring accessible solutions to this critical issue, Cell Constructs is changing its name to ProgenaCare Global to reflect its pioneering of a brand-new approach. The company…

Dive Brief: Amgen has agreed to acquire privately held biotech Teneobio for as much as $2.5 billion in a deal meant to broaden the big biotech’s ability to develop antibody drugs for cancer and potentially other diseases.   Per deal terms, Amgen will pay $900 million in cash for Teneobio and could add another $1.6 billion in downstream…

ATLANTA, July 27, 2021 /PRNewswire/ — MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe®).  The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from…

PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad range of chronic and rare conditions, as well as urgent new health challenges like COVID-19. From new data released today, in 2020 alone, PhRMA member…

Acquisition of Velano Vascular Adds Innovative Needle-Free Blood Draw Technology to Reduce Pain and Discomfort of Multiple Needlesticks FRANKLIN LAKES, N.J., July 20, 2021 /PRNewswire/ –BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has taken a large step forward in transforming the patient experience through a vision of a “One-Stick…

To make it easier to draw connections between changes in individual genes, the resulting structure of the proteins they code for and their ultimate impacts on human health and disease, a trio of Big Pharma companies has launched a publicly available search engine to parse genomic data from over 280,000 people. Maintained by the Broad Institute…

On Monday, a World Health Organization advisory committee called on the world’s largest public health authority to stand by the 2019 statement of its director-general urging a halt to any experiments that might lead to the births of more gene-edited humans. The committee — established in December 2018, weeks after news broke of the birth of twin…

– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine – ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. The…

Funding Will Advance Technologies for Plastic Recycling, Reduce Plastic Waste, and Cut the Carbon Footprint of Plastic Production WASHINGTON, D.C. — The U.S. Department of Energy (DOE) today announced an investment of up to $14.5 million for research and development to cut waste and reduce the energy used to recycle single-use plastics like plastic bags, wraps,…